| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Cdc73; FIHP; HPTJT; HRPT1; HRPT2; Hyperparathyroidism 2; HYX;;Parafibromin |
| WB Predicted band size | 61 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthesized peptide derived from human Parafibromin |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是3-4篇关于 **HRPT2/CDC73抗体** 的参考文献及其简要摘要：
---
1. **文献名称**: *Parafibromin Immunohistochemistry in the Diagnosis of Parathyroid Cancer*
**作者**: Gill AJ, et al.
**摘要**: 研究探讨了parafibromin(由HRPT2/CDC73编码的蛋白)抗体在甲状旁腺癌诊断中的应用，发现其在恶性肿瘤中普遍表达缺失，可作为区分良恶性病变的标志物。
2. **文献名称**: *HRPT2 Mutations and CDC73 Antibody Staining in Parathyroid Tumors*
**作者**: Howell VM, et al.
**摘要**: 通过分析HRPT2突变与parafibromin表达的关系，发现CDC73抗体检测能有效识别突变相关肿瘤，支持其在遗传性和散发性甲状旁腺癌中的诊断价值。
3. **文献名称**: *Loss of Nuclear Expression of Parafibromin in Carcinomas of Head and Neck*
**作者**: Bradley KJ, et al.
**摘要**: 研究利用CDC73抗体检测头颈部肿瘤中parafibromin的表达，发现部分肿瘤(如甲状旁腺癌)存在核表达缺失，提示其作为分子标记的潜在用途。
4. **文献名称**: *CDC73/HRPT2 Mutation Analysis and Parafibromin Antibody Specificity*
**作者**: Juhlin CC, et al.
**摘要**: 评估了多种商业CDC73抗体的敏感性和特异性，确认其在检测HRPT2突变相关肿瘤中的可靠性，并优化了免疫组化实验条件。
---
以上文献聚焦于HRPT2/CDC73抗体在肿瘤(尤其是甲状旁腺癌)中的诊断应用、突变关联分析及抗体技术验证。如需具体期刊或年份信息，可进一步补充说明。
The HRPT2 gene, also known as CDC73. encodes the protein parafibromin, a tumor suppressor implicated in cell cycle regulation and transcriptional modulation through its interaction with the PAF1 complex. Germline mutations in HRPT2 are linked to hyperparathyroidism-jaw tumor (HPT-JT) syndrome, an autosomal dominant disorder characterized by parathyroid adenomas/carcinomas, ossifying jaw tumors, and renal lesions. Somatic HRPT2 mutations are also observed in sporadic parathyroid carcinomas and a subset of renal and thyroid tumors.
Antibodies targeting the HRPT2/CDC73 gene product (parafibromin) are primarily utilized in research and diagnostics to assess protein expression levels. Loss of nuclear parafibromin expression, detected via immunohistochemistry (IHC), serves as a biomarker for HRPT2 inactivation, aiding in the distinction of parathyroid carcinoma from benign adenomas. These antibodies have also facilitated studies exploring parafibromin's role in Wnt/β-catenin signaling, histone modification, and cell proliferation.
Clinically, HRPT2/CDC73 antibody testing supports the diagnosis of HPT-JT syndrome and guides surveillance in high-risk individuals. However, interpretation requires caution, as aberrant staining patterns may arise from technical variability or non-inactivating mutations. Ongoing research aims to refine its utility in prognostication and targeted therapies for HRPT2-deficient tumors.
×
